AKT1 and acute lymphoblastic leukemia: With the above in mind, we decided to undertake a comprehensive study where different inhibitors were tested under the same conditions, against T-ALL cells (both cell lines and primary samples from patients) displaying constitutive PI3K/Akt/mTOR activation.